- Home
- SLN vs HSHP Comparison
SLN vs HSHP Comparison
Compare SLN & HSHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- HSHP
- Stock Information
- Founded
- SLN 1994
- HSHP 2021
- Country
- SLN United Kingdom
- HSHP Bermuda
- Employees
- SLN N/A
- HSHP N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- HSHP
- Sector
- SLN Health Care
- HSHP
- Exchange
- SLN Nasdaq
- HSHP Nasdaq
- Market Cap
- SLN 345.3M
- HSHP 395.7M
- IPO Year
- SLN N/A
- HSHP 2023
- Fundamental
- Price
- SLN $6.67
- HSHP $9.01
- Analyst Decision
- SLN Buy
- HSHP
- Analyst Count
- SLN 6
- HSHP 0
- Target Price
- SLN $39.67
- HSHP N/A
- AVG Volume (30 Days)
- SLN 212.8K
- HSHP 128.6K
- Earning Date
- SLN 11-06-2025
- HSHP 11-06-2025
- Dividend Yield
- SLN N/A
- HSHP 5.32%
- EPS Growth
- SLN N/A
- HSHP N/A
- EPS
- SLN N/A
- HSHP 0.11
- Revenue
- SLN $25,830,000.00
- HSHP $119,380,000.00
- Revenue This Year
- SLN N/A
- HSHP $7.01
- Revenue Next Year
- SLN N/A
- HSHP $20.02
- P/E Ratio
- SLN N/A
- HSHP $78.79
- Revenue Growth
- SLN 40.39
- HSHP 6.29
- 52 Week Low
- SLN $1.97
- HSHP $4.29
- 52 Week High
- SLN $8.88
- HSHP $9.04
- Technical
- Relative Strength Index (RSI)
- SLN 55.39
- HSHP 73.12
- Support Level
- SLN $5.91
- HSHP $8.15
- Resistance Level
- SLN $6.62
- HSHP $8.37
- Average True Range (ATR)
- SLN 0.51
- HSHP 0.18
- MACD
- SLN -0.05
- HSHP 0.11
- Stochastic Oscillator
- SLN 81.25
- HSHP 98.16
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.